title: A PCR-based microwell-plate hybrid capture assay for high-risk human papillomavirus.
abstract: Human papillomavirus (HPV) is associated with cervical cancer. In this study, we developed a high-throughput microwell-plate hybrid capture (MPHC) method for epidemiological studies of high-risk HPV (HRHPV). The results with 1238 cervical specimens from female outpatients showed a concordance rate of 94.3 % between the MPHC and Hybrid Capture II assay. The MPHC assay showed an average HRHPV rate of 29.3 % for high-risk populations in populous cities of China. The established MPHC assay could sensitively and specifically detect 13 types of HRHPV and is suitable for large-scale screening, especially in areas where real-time PCR or fluorescence equipment is unavailable.
authors.affiliation: Department of In Vitro Diagnostic Reagents, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing, 100050, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yaping
authors.initials: Y
authors.lastname: Ding
authors.forename: Nan
authors.initials: N
authors.lastname: Sun
authors.forename: Yafang
authors.initials: Y
authors.lastname: Gong
authors.forename: Shangxian
authors.initials: S
authors.lastname: Gao
mesh_terms: D002681:China; D002947:Cities; D006801:Humans; D008403:Mass Screening / Q000379:methods; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D017720:Molecular Epidemiology / Q000379:methods; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis*; D016133:Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity
references.citation: J Clin Microbiol. 1998 Nov;36(11):3248-54
references.pmid: 9774574
references.citation: BMC Infect Dis. 2003 Sep 25;3:23
references.pmid: 14511396
references.citation: Cancer. 2007 Oct 25;111(5):339-43
references.pmid: 17879373
references.citation: J Clin Microbiol. 2012 Jun;50(6):1867-73
references.pmid: 22422852
references.citation: Virology. 2009 Feb 20;384(2):260-5
references.pmid: 19135222
references.citation: Lancet Oncol. 2010 Mar;11(3):249-57
references.pmid: 20089449
references.citation: Future Virol. 2011 Jan 1;6(1):45-57
references.pmid: 21318095
references.citation: J Clin Virol. 2009 Feb;44(2):106-10
references.pmid: 19144564
references.citation: Chem Commun (Camb). 2013 Nov 21;49(90):10605-7
references.pmid: 24098886
references.citation: Int J Gynecol Cancer. 2012 Nov;22(9):1570-6
references.pmid: 23051954
references.citation: Vaccine. 2013 Dec 29;31 Suppl 5:F53-9
references.pmid: 24331748
references.citation: Asian Pac J Cancer Prev. 2013;14(7):4015-23
references.pmid: 23991946
references.citation: Asian Pac J Cancer Prev. 2013;14(9):5519-25
references.pmid: 24175852
references.citation: J Clin Virol. 2009 Jul;45 Suppl 1:S85-92
references.pmid: 19651374
references.citation: J Obstet Gynaecol Res. 2009 Aug;35(4):706-11
references.pmid: 19751331
references.citation: Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):279-82
references.pmid: 17696746
references.citation: Vaccine. 2013 Dec 31;31 Suppl 7:H46-58
references.pmid: 24332297
references.citation: J Low Genit Tract Dis. 2013 Jul;17(3):308-14
references.pmid: 23552206
references.citation: APMIS. 2010 Jun;118(6-7):471-93
references.pmid: 20553529
references.citation: BMJ. 2011 May 23;342:d2757
references.pmid: 21606136
references.citation: Braz J Infect Dis. 2006 Oct;10(5):331-6
references.pmid: 17293921
references.citation: Med Arh. 2007;61(3):135-7
references.pmid: 18232273
references.citation: Public Health Genomics. 2009;12(5-6):268-80
references.pmid: 19684440
references.citation: Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
references.pmid: 23199955